TECNOLOGÍA PARA LA MONITORIZACIÓN Y CONTROL DE LA DIABETES

VolverVolver

Resultados 100 resultados LastUpdate Última actualización 27/09/2020 [18:40:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



previousPage Página2 de 4 nextPage   por página


DIABETES MANAGEMENT PARTNER INTERFACE FOR WIRELESS COMMUNICATION OF ANALYTE DATA

NºPublicación: EP3704912A1 09/09/2020

Solicitante:

DEXCOM INC [US]

CN_111247853_A

Resumen de: US2019132801A1

Systems, devices, and methods are disclosed for wireless communication of analyte data. In embodiments, a method of using a diabetes management partner interface to configure an analyte sensor system for wireless communication with a plurality of partner devices is provided. The method includes the analyte sensor system receiving authorization to provide one of the partner devices with access to a set of configuration parameters via the diabetes management partner interface. The set of configuration parameters is stored in a memory of the analyte sensor system. The method also includes, responsive to input received from the one partner device via the diabetes management partner interface, the analyte sensor system setting or causing a modification to the set of configuration parameters, according to a system requirement of the one partner device.

traducir

SYSTEM AND METHOD FOR ELECTRICAL NERVE AND MUSCLE STIMULATION

NºPublicación: WO2020176050A1 03/09/2020

Solicitante:

SANOTECH TEKNOLOJI SANAYI TICARET LTD SIRKETI [TR]

Resumen de: WO2020176050A1

The invention concerns a wireless, wearable electrical nerve and muscle stimulation system and method designed for the purpose of alleviating the abnormal foot sensations such as burning, stinging and pain experienced especially by diabetes patients.

traducir

SYSTEMS, DEVICES, AND METHODS FOR ALLEVIATING GLUCOTOXICITY AND RESTORING PANCREATIC BETA-CELL FUNCTION IN ADVANCED DIABETES MELLITUS

NºPublicación: US2020275884A1 03/09/2020

Solicitante:

HYGIEIA INC [US]

US_2014343530_PA

Resumen de: US2020275884A1

Systems, methods and/or devices for treating diabetes mellitus by alleviating glucotoxicity and restoring pancreatic beta-cell function, comprising at least a first memory for storing data inputs corresponding at least to one or more components in a patient's present insulin dosage regimen, and data inputs corresponding at least to the patient's blood-glucose-level measurements determined at a plurality of times, and a processor operatively connected to the at least first memory. The processor is programmed at least to determine from the data inputs corresponding to the patient's blood-glucose-level measurements determined at a plurality of times whether and by how much to vary at least one of the components of the patient's present insulin dosage regimen. Also disclosed are systems, methods, and/or devices for alleviating glucotoxicity and restoring pancreatic beta-cell function, comprising establishing the patient's current glycemic state relative to a desired glycemic range and determining from at least one of a plurality of the data corresponding to the patient's blood glucose-level measurements whether and by how much to adjust at least one of the components in the patient's present insulin dosage regimen.

traducir

GLUCOSE TEST ARRANGEMENT AND METHOD

NºPublicación: US2020275868A1 03/09/2020

Solicitante:

ROCHE DIABETES CARE INC [US]

JP_2020524800_A

Resumen de: US2020275868A1

A glucose test arrangement is provided for use in a handheld meter. The arrangement comprises a disposable test pad responsive to glucose in a body fluid, and a supporting member adapted to support the test pad at an application site for applying body fluid from a user's skin onto a receiving area of the test pad. The receiving area faces away from the supporting member. One or more spacer elements are arranged on the supporting member adjacent to the test pad, wherein the one or more spacer elements have a skin-contacting end section which protrudes above the receiving area.

traducir

Implantable Glucose Monitor

NºPublicación: US2020275867A1 03/09/2020

Solicitante:

SANOFI SA [FR]

WO_2019101612_PA

Resumen de: US2020275867A1

Implantable device for measuring the glucose concentration of a body fluid when implanted, the implantable device comprising a glucose measurement unit, the glucose measurement unit comprising a first light source configured to emit light towards a light transmissive part of a housing of the device and a first optical sensor configured to detect light returned through the light transmissive part from the first light source, and output a first electrical signal based on the detected light; and a wireless communication module configured to wirelessly communicate with an external wireless communication device, wherein the wireless communication module is configured to wirelessly transmit a signal based on the first electrical signal to the external wireless communication device.

traducir

Implantable Glucose Monitor

NºPublicación: US2020275866A1 03/09/2020

Solicitante:

SANOFI SA [FR]

WO_2019101611_PA

Resumen de: US2020275866A1

Implantable device for measuring the glucose concentration of a body fluid when implanted, the device comprising a glucose measurement unit, the glucose measurement unit comprising a light source configured to emit light towards a light transmissive part of a housing of the device, the device further comprising an optical sensor configured to detect light returned through the transmissive part from the light source, and output an electrical signal based on the detected light, and a wireless communication module configured to wirelessly communicate with an external wireless communication device, wherein the wireless communication module is configured to wirelessly transmit a signal based on the electrical signal to the external wireless communication device.

traducir

Devices, methods, and systems for the treatment and/or monitoring of damaged tissue

NºPublicación: AU2019217431A1 03/09/2020

Solicitante:

ADLORE INC

WO_2019156951_A1

Resumen de: AU2019217431A1

Disclosed are methods, devices, and systems for treatment of an abnormal wound healing response. The methods, devices, and systems can be used to treat solid ulcerated tissue, such as diabetic foot ulcers (DFUs), arthritic tissue, muscle soreness, joint pain, varicose veins, obesity, and peripheral artery disease. Additionally, the methods, devices, and systems can promote the healing of xenograft, allograft, autograft, or engineered tissue following reconstruction surgery. The methods, devices, and systems include the ability to determine an optimal set of pulse parameters that are specific to wound healing. In embodiments, the methods, devices, and systems include components for guiding the user on electrode placement based on anatomical or electrical measurements, delivering a custom series of electric pulses, applying heat, and using feedback from physiologic measurements to control the device.

traducir

ELECTRONIC DEVICE AND CONTROL METHOD THEREFOR

NºPublicación: US2020275865A1 03/09/2020

Solicitante:

SAMSUNG ELECTRONICS CO LTD [KR]

KR_20180106783_A

Resumen de: US2020275865A1

An electronic device and a control method therefor are disclosed. The electronic device control method according to the present invention comprises the steps of: receiving blood glucose information and skin temperature information from a blood glucose meter; obtaining external temperature information of a region in which a user wearing the blood glucose meter is located; determining, by using the skin temperature information and the external temperature information, the predictive temperature of an inner skin part at which an enzyme sensor of the blood glucose meter is located; correcting the blood glucose information on the basis of the determined predictive temperature; and outputting the corrected blood glucose information. Therefore, even if the skin temperature rapidly rises or falls because of the external temperature, the electronic device can provide a result similar to the blood glucose value, measured by a disposable blood glucose meter, by correcting a blood glucose value in consideration of the temperature in the skin into which the sensor of a blood glucose meter for measuring blood glucose is inserted.

traducir

METHOD FOR COMPLEX ASSESSMENT OF ARTERIAL BED STATE

NºPublicación: RU2731414C1 02/09/2020

Solicitante:

SHCHEKOCHIKHIN SERGEJ ANATOLEVICH [RU]

Resumen de: RU2731414C1

FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to a method for complex estimation of arterial bed state. Finger area is irradiated with a light signal of the red and infrared wavelength ranges. Ambient temperature and temperature of the finger area to be recorded are pre-stabilized and the clamp of the emitters and the photodetector to the finger is adjusted. Photoplethysmographic (PPG) signal is recorded for at least 5 minutes. PPG signal is contoured by signal filtration by Savitzky-Golay method with 64 ms window width and obtaining the fourth signal derivative. Direct and reflected wave of PPG signal is detected from the artery wall. Arterial stiffness is determined on the basis of time interval between direct and reflected waves and on the basis of their amplitudes. Complex continuous wavelet transformation of the PPG signal is carried out using a Morlet basis wavelet and generating a wavelet spectrum. Peak location of PPG signal power in the wavelet spectrum is determined. State of the microcirculatory bed is assessed by the arrangement of peaks in the frequency ranges corresponding to the microvascular tonus regulation mechanism.EFFECT: invention provides accuracy, simplicity, reliability and reduced time for examination with integrated assessment of vascular bed for early diagnosis of widespread diseases - arterial hypertension and diabetes, in pathogenesis of which damage of arterial bed is of primary importance.5 cl, 4 ex, 16 dwg

traducir

METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR CGM-BASED PREVENTION OF HYPOGLYCEMIA VIA HYPOGLYCEMIA RISK ASSESSMENT AND SMOOTH REDUCTION INSULIN DELIVERY

NºPublicación: EP3703066A1 02/09/2020

Solicitante:

THE UNIV OF VIRGINIA PATENT FOUNDATION [US]

US_2017337348_A1

Resumen de: EP3703066A1

An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.

traducir

Hydrating mouth guard

NºPublicación: US10758329B1 01/09/2020

Solicitante:

WRIGHT III RAYMOND L [US]

Resumen de: US10758329B1

A transmucosal delivery device includes a mouthpiece configured for receipt on a user's teeth, a permeable member coupled to the mouthpiece, a measurement module coupled to the mouthpiece for monitoring hydration of the user, and an excitation module coupled to the mouthpiece for inducing release of a hydrating substance from the permeable member based on the monitored hydration. The hydrating substance is delivered to the user through the user's oral mucosal tissue. Alternatively, a permeable member of a transmucosal delivery device houses an insulin solution to be delivered to the user through the user's oral mucosal tissue, and a measurement module coupled to the mouthpiece for monitoring blood glucose concentration of the user.

traducir

Reprogrammed beta cells from adult stem cells

NºPublicación: US10760059B1 01/09/2020

Solicitante:

INGENERON INC [US]

Resumen de: US10760059B1

Methods of differentiating unmodified adult stem cells into functional beta-like cells are provided, as well as compositions, tissues and devices containing such cells. The method requires inducing sequential expression of PDX1, NGN3, and MAFA in these stem cells to form reprogrammed beta cells. Methods of treating diabetes are also provided, comprising obtaining stem cells, preferably from a patient with diabetes, inducing sequential expression of PDX1, NGN3, and MAFA, in said stem cells to form reprogrammed beta cells, and introducing said reprogrammed beta cells into a pancreas of said patient. Alternatively, it may be possible to inject such cells systemically, if the cells are targeted for the pancreas. In yet another embodiment, the reprogrammed beta cells are placed into an artificial pancreas that is surgically placed or injected into the patient.

traducir

METHODS AND APPARATUS FOR ANALYTE CONCENTRATION MONITORING USING HARMONIC RELATIONSHIPS

NºPublicación: US2020268323A1 27/08/2020

Solicitante:

ASCENSIA DIABETES CARE HOLDINGS AG [CH]

US_2020268290_A1

Resumen de: US2020268323A1

Continuous glucose monitoring (CGM) may include applying a periodic excitation signal via an electrode of a CGM sensor to human interstitial fluid to drive an oxidation/reduction reaction, and measuring the current through the electrode. In some embodiments, the measured current is sampled and digitized, and various harmonics of the excitation signal's fundamental frequency are extracted. A set of relationships of at least two harmonics each is generated from the spectral amplitudes of a set of pairs, triplets, etc., of the harmonics, and the set of relationships is mapped to a glucose concentration such as based on the contents of a harmonic relationship database having a pre-existing set of harmonic relationships and glucose concentrations to which those sets of harmonic relationships correspond, for example. Numerous other embodiments are provided.

traducir

RECEIVERS FOR ANALYZING AND DISPLAYING SENSOR DATA

NºPublicación: US2020268325A1 27/08/2020

Solicitante:

DEXCOM INC [US]

US_2020037965_A1

Resumen de: US2020268325A1

This disclosure provides systems, methods and apparatus for processing, transmitting and displaying data received from an analyte sensor, such as a glucose sensor. The system may include a display device with at least one input device. In response to movement of or along the input device, the display device may change a glucose data output parameter and update an output of the display device using the changed output parameter.

traducir

MEDIATION OF IN VIVO ANALYTE SIGNAL DEGRADATION

NºPublicación: US2020268291A1 27/08/2020

Solicitante:

SENSEONICS INCORPORATED [US]

WO_2020172540_A1

Resumen de: US2020268291A1

A sensor (e.g., an optical sensor) that may be implanted within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a sensor housing, an analyte indicator covering at least a portion of the sensor housing, and one or more compounds containing boronate or boronic acid moieties that reduce degradation of the analyte indicator.

traducir

METHODS AND SYSTEMS FOR MANAGING DIABETES

NºPublicación: US2020268968A1 27/08/2020

Solicitante:

CHILDREN`S MEDICAL CENTER CORP [US]
JOSLIN DIABETES CENTER INC [US]

WO_2017184988_A1

Resumen de: US2020268968A1

This disclosure relates to systems and methods for diabetes management.

traducir

METHODS AND APPARATUS FOR ANALYTE CONCENTRATION MONITORING USING HARMONIC RELATIONSHIPS

NºPublicación: US2020268290A1 27/08/2020

Solicitante:

ASCENSIA DIABETES CARE HOLDINGS AG [CH]

US_2020268323_A1

Resumen de: US2020268290A1

Continuous glucose monitoring (CGM) may include applying a periodic excitation signal via an electrode of a CGM sensor to human interstitial fluid to drive an oxidation/reduction reaction, and measuring the current through the electrode. In some embodiments, the measured current is sampled and digitized, and various harmonics of the excitation signal's fundamental frequency are extracted. A set of relationships of at least two harmonics each is generated from the spectral amplitudes of a set of pairs, triplets, etc., of the harmonics, and the set of relationships is mapped to a glucose concentration such as based on the contents of a harmonic relationship database having a pre-existing set of harmonic relationships and glucose concentrations to which those sets of harmonic relationships correspond, for example. Numerous other embodiments are provided.

traducir

INSULIN DELIVERY ARRANGEMENT AND METHOD FOR INSULIN DOSING

NºPublicación: WO2020169706A1 27/08/2020

Solicitante:

MYSUGR GMBH [AT]

Resumen de: WO2020169706A1

The invention concerns an insulin delivery arrangement (10) comprising a hand-operable insulin delivery device (12) which includes an adjusting unit (14) for presetting of an insulin dose and an applicator unit (24) that can be triggered to deliver the preset insulin dose to a user. In order to ease burden of insulin dosing, a dose converter (16) is adapted to receive an actual setting for the insulin dose as an input and to provide as an output a carbohydrate value equivalent to an amount of meal carbohydrates which can be compensated by the respective insulin dose, and a display (20, 20', 20'') is used for displaying the carbohydrate value in parallel to the insulin dose.

traducir

MEDIATION OF IN VIVO ANALYTE SIGNAL DEGRADATION

NºPublicación: WO2020172540A1 27/08/2020

Solicitante:

SENSEONICS INCORPORATED [US]

US_2020268291_A1

Resumen de: WO2020172540A1

A sensor (e.g., an optical sensor) that may be implanted within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a sensor housing, an analyte indicator covering at least a portion of the sensor housing, and one or more compounds containing boronate or boronic acid moieties that reduce degradation of the analyte indicator.

traducir

WEARABLE APPARATUS FOR CONTINUOUS BLOOD GLUCOSE MONITORING

NºPublicación: US2020272319A1 27/08/2020

Solicitante:

DEXCOM INC [US]

AU_2020203210_A1

Resumen de: US2020272319A1

A system, a method, and a computer program product for providing wearable continuous blood glucose monitoring. In some embodiments, there is provided a method that includes receiving, at a smartwatch, an alert representative of a glucose state of a host-patient coupled to a glucose sensor; detecting, at the smartwatch, a predetermined action indicative of a request to generate a glance view providing an indication of the glucose state of the host-patient; and presenting, at the smartwatch and in response to the detecting, the glance view providing the indication of the glucose state of the host-patient.

traducir

STABLE PROTEIN SOLUTION FORMULATION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY

NºPublicación: US2020270336A1 27/08/2020

Solicitante:

NOVARTIS AG [CH]

JP_2020079242_A

Resumen de: US2020270336A1

The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.

traducir

BLOOD GLUCOSE SENSING SYSTEM AND METHOD FOR CORRECTING HEMATOCRIT

NºPublicación: KR20200100396A 26/08/2020

Solicitante:

CT INTEGRATED SMART SENSORS FOUND [KR]

Resumen de: KR20200100396A

본 발명은 적혈구 용적률 보정이 가능한 혈당 측정 시스템을 제공한다.

traducir

METHOD FOR RAPID ASSESSMENT OF RISK OF TYPE 2 DIABETES MELLITUS OR PRE-DIABETES IN INDIVIDUALS OF THE RUSSIAN POPULATION

NºPublicación: RU2730949C1 26/08/2020

Solicitante:

FEDERALNOE GOSUDARSTVENNOE BYUDZHETNOE UCHREZHDENIE NATSIONALNYJ MEDITSINSKIJ ISSLEDOVATELSKIJ TSENT [RU]

Resumen de: RU2730949C1

FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to endocrinology and diabetology. Following parameters are determined in the Russian population: patient's age, intake of preparations for correction of high blood cholesterol, diagnosis of DM type 2 in blood relatives, presence of arterial hypertension, regular physical activity, consumption of preserved and/or smoked and/or excessively salty products; measurement of body weight and growth of patient, based on which is calculated value of body weight index (BWI), determination of sugar level in capillary/venous blood, measurement of waist and hip circumference, determination of waist circumference to hip circumference, measurement of systolic AP. Points are assigned to the obtained values and summed up. And if the value is less than 7 points, absence of impaired glucose tolerance is determined. At less than 11 points, but more than or equal to 7 points, high risk of pre-diabetes is determined. When obtaining "1 and more points" - high risk of presence of DM type 2 is determined.EFFECT: method enables higher accuracy of diagnosing the disease, reducing an unfavorable prognosis of developing complications of diabetes, as well as detecting a risk group of patients without missing boundary conditions.1 cl, 2 tbl, 1 dwg, 3 ex

traducir

OXYNTOMODULIN PEPTIDE ANALOG FORMULATIONS

NºPublicación: US2020262887A1 20/08/2020

Solicitante:

OPKO IRELAND GLOBAL HOLDINGS LTD [KY]

WO_2020109526_A2

Resumen de: US2020262887A1

The present invention relates to GLP-1 and/or glucagon receptor agonists (for example, oxyntomodulin peptide analogs), pharmaceutically acceptable salts thereof, formulations comprising the same, and uses thereof for treating diabetes and/or obesity or associated diseases or disorders.

traducir

METHOD AND APPARATUS FOR ELECTRICAL CURRENT THERAPY OF BIOLOGICAL TISSUE AND INSULIN RELEASE THEREFROM

Nº publicación: WO2020168164A1 20/08/2020

Solicitante:

MOWER MORTON M [US]

US_2020261730_A1

Resumen de: WO2020168164A1

The present disclosure relates to a device for applying electrical stimulation to biological tissues. Specifically, the present disclosure is related to a device for applying anodal/cathodal biphasic electrical stimulation to beta cells of the pancreas. Through application of biphasic stimulation to beta cells of the pancreas, insulin secretion can be increased in an effort to overcome deficiencies associated with diabetic patients.

traducir

previousPage Página2 de 4 nextPage por página

punteroimgVolver